Phone: 614/488-2118
Fax: 614/488-2647

1335 Dublin Rd., Suite 124A
Columbus, OH 43215

Protocol Categories

View All Protocols


Multiple Disease Sites

ECOG EAY131 MASTER
Molecular Analysis for Therapy Choice (MATCH)
ECOG EAY131 Subprotocol A
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG EAY131 Subprotocol C2
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG EAY131 Subprotocol E
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR 790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG EAY131 Subprotocol F
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations
ECOG EAY131 Subprotocol G
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
ECOG EAY131 Subprotocol J
MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG EAY131 Subprotocol K1
MATCH Treatment Subprotocol K1: Phase 2Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Amplifications
ECOG EAY131 Subprotocol K2
MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions
ECOG EAY131 Subprotocol L
MATCH Treatment Subprotocol L : Phase II Study of MLN0128(TAK-228)in Patients with Tumors with mTOR Mutations, to be incorporated into the EAY131 Master Protocol in Addendum #7
ECOG EAY131 Subprotocol M
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG EAY131 Subprotocol S2
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 Mutations
ECOG EAY131 Subprotocol T
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1)Mutations
ECOG EAY131 Subprotocol V
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GITS, Renal Cell Carcinoma or Pancreatic Neuroendocine Tumor)
ECOG EAY131 Subprotocol Z1E
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG EAY131 Subprotocol Z1G
MATCH Treatment Subprotocol Z1G: Phase 2 STudy of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result
ECOG EAY131 Subprotocol Z1H
MATCH Treatment Subprotocol Z1H: Phase 2 STudy of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC
SWOG S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors